Ditchcarbon
  • Contact
  1. Organizations
  2. Epizyme, Inc.
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Pharmaceutical Preparation Manufacturing
US
updated a day ago

Epizyme, Inc.

Company website

Epizyme, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2008, Epizyme has made significant strides in the field of epigenetics, focusing on the discovery and development of small molecule drugs that target specific genetic mutations. The company’s flagship product, Tazemetostat, is a first-in-class EZH2 inhibitor that has garnered attention for its unique mechanism of action and potential to treat various malignancies. With a strong commitment to advancing precision medicine, Epizyme has established a notable market position, particularly in the oncology sector, and continues to expand its pipeline of targeted therapies. Through its dedication to scientific excellence, Epizyme is shaping the future of cancer treatment and improving patient outcomes.

DitchCarbon Score

How does Epizyme, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

83

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Epizyme, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

89%

Let us know if this data was useful to you

Epizyme, Inc.'s reported carbon emissions

Inherited from Ipsen S.A.

Epizyme, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Ipsen S.A., which means that any climate commitments or emissions data may be inherited from its parent organisation. As a subsidiary, Epizyme's climate initiatives and targets are aligned with those of Ipsen S.A. However, specific reduction targets or achievements for Epizyme itself have not been disclosed. The company does not have any documented reduction targets or climate pledges at this time. For context, Ipsen S.A. has established various climate initiatives, which may influence Epizyme's approach to sustainability and emissions management. As of now, Epizyme's commitment to addressing climate change remains vague, with no specific metrics or targets available for public review.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20192021202220232024
Scope 1
14,316,000
00,000,000
00,000,000
00,000,000
0,000,000
Scope 2
4,343,000
0,000,000
0,000,000
000,000
000,000
Scope 3
121,718,000
00,000,000
00,000,000
-
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Epizyme, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Epizyme, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Epizyme, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Otsuka Pharmaceutical

JP
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Spectrum Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Forma Therapeutics Holdings, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 26 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251009.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy